


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-27 (Canceled).

28. (New): A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

a is 0, 1, 2 or 3;

b is 1, 2 or 3;

Y is carbon;

A is oxygen;

R^1 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, hydroxy, amino, mono- or di- C_{1-6} alkylamino, nitro, CN, CF_3 or OCF_3 ;

R^2 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl or halo C_{1-6} alkoxy;

R^3 is an optionally substituted N-linked heterocycle or di C_{1-6} alkylamino;

wherein said optionally substituted N-linked heterocycle is pyrrolidinyl, piperazinyl, morpholinyl, imidazolidinyl, thiomorpholinyl, piperidinyl or azepanyl;

==== is a single bond or a double bond;

X is CH_2 when ==== is a single bond or X is CH when ==== is a double bond.

29. (New): The compound or salt according to claim 28 wherein a is 1 or 2.


30. (New): The compound or salt according to claim 28 wherein R^1 is halogen.

31. (New): The compound or salt according to claim 28 wherein R^1 is at the 3 position or the 4 position.


32. (New): The compound or salt according to claim 28 wherein R^2 is C_{1-6} alkoxy.

33. (New): The compound or salt according to claim 28 wherein b is 2.

34. (New): The compound or salt according to claim 28 having the formula:



35. (New): The compound or salt according to claim 28 having the formula:



36. (New): The compound or salt according to claim 28 wherein: a is 1 or 2; b is 2; R^1 is halogen; R^2 is C_{1-6} alkoxy; R^3 is morpholinyl, piperidinyl, or diC_{1-6} alkylamino.

37. (New): The compound or salt according to claim 34 wherein: a is 1 or 2; b is 2; R^1 is halogen; R^2 is C_{1-6} alkoxy; R^3 is morpholinyl, piperidinyl, or diC_{1-6} alkylamino.

38. (New): The compound or salt according to claim 35 wherein: a is 1 or 2; b is 2; R^1 is halogen; R^2 is C_{1-6} alkoxy; R^3 is morpholinyl, piperidinyl, or diC_{1-6} alkylamino.

39. (New): The compound according to claim 28, which is:

1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazolidin-2-one;

1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-phenyl]-
imidazolidin-2-one;

1-(4-Methyl-3-trifluoromethyl-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-
phenyl]-imidazolidin-2-one;

1-(4-Methyl-3-trifluoromethyl-phenyl)-3-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-
phenyl]-imidazolidin-2-one;

1-(2-Chloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazolidin-
2-one;

1-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-phenyl-imidazolidin-2-one;

1-[3-(2-Dimethylamino-ethoxy)-4-methoxy-phenyl]-3-(3-fluorophenyl)-imidazolidin-
2-one;

1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-
imidazolidin-2-one;

1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-phenyl]-
imidazolidin-2-one;

1-(3,4-Dichloro-phenyl)-3-[3-(2-dimethylamino-ethoxy)-4-methoxy-phenyl]-
imidazolidin-2-one;

1-[4-Bromo-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-
imidazolidin-2-one;

1-(2,3-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-
imidazolidin-2-one;

1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,3-dihydro-
imidazol-2-one;

1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,3-dihydro-
imidazol-2-one;

1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazol-2-
one;

or a pharmaceutically acceptable salt thereof.

40. (New): A pharmaceutical composition comprising the compound or salt
according to claim 28 and a pharmaceutically acceptable carrier or excipient.

41. (New): The pharmaceutical composition of Claim 40, further comprising another compound which is a selective serotonin reuptake inhibitor or a noradrenaline re-uptake inhibitor.

42. (New): A process for preparing a pharmaceutical composition as defined in claim 40, the process comprising mixing the compound or salt as defined in claim 28 and a pharmaceutically acceptable carrier or excipient.

43. (New): A process for preparing a pharmaceutical composition as defined in claim 41, the process comprising mixing the compound or salt as defined in claim 28, another compound which is a selective serotonin reuptake inhibitor or a noradrenaline re-uptake inhibitor, and a pharmaceutically acceptable carrier or excipient.

44. (New): A method of treating anxiety in a human which comprises administering to said human a therapeutically effective amount of the compound or salt according to claim 28.

45. (New): A method of treating depression in a human which comprises administering to said human a therapeutically effective amount of a pharmaceutical composition comprising the compound or salt according to claim 28 and another compound which is a selective serotonin reuptake inhibitor or a noradrenaline re-uptake inhibitor.

46. (New): A method of treating anxiety in a human which comprises administering to said human a therapeutically effective amount of the composition as defined in claim 40.

47. (New): A method of treating depression in a human which comprises administering to said human a therapeutically effective amount of the composition as defined in claim 41.